Tag Archives: The Stem Cell Blog

‘Epigenetic CRISPR’ edits DNA without cutting it | FierceBiotech – FierceBiotech

Continue reading

2017-12-08 NEWS

FierceBiotech

‘Epigenetic CRISPR’ edits DNA without cutting it | FierceBiotech
FierceBiotech
A Salk Institute team created a form of CRISPR/Cas9 that activates specific genes without making breaks in the DNA, which can cut down on harmful side effects.
CRISPR/Cas9 can reverse multiple diseases in miceScience News
Diabetes and muscular dystrophy could be treated effectively with modified Crispr genetic engineering techniqueThe Independent
CRISPR/Cas9 Edits Epigenome with Therapeutic EfficiencyGenetic Engineering & Biotechnology News

all 52 news articles »

Continue reading

2017-12-08 NEWS

Physical therapy essential to Andrews Institute’s stem cell knee cartilage trial — 3 insights
Becker’s Orthopedic & Spine
Physical therapy is playing an important role in a clinical trial being conducted at Gulf Breeze, Fla.-based Andrews Institute for Orthopaedics & Sports Medicine, where stem cells are being used to regenerate knee cartilage. Here’s what you should know

Continue reading

2017-12-08 NEWS

5newsonline.com

DNA Is Going Digital – What Could Possibly Go Wrong?
5newsonline.com
We’ve even hosted FBI agents from the Weapons of Mass Destruction Directorate here at Colorado State University and previously at Virginia Tech for crash courses on synthetic biology and the associated cyberbiosecurity risks. A year ago, we

and more »

Continue reading

2017-12-08 NEWS

Coos Bay World

Gene therapy shows promise against blood-clotting disease
Coos Bay World
The therapy supplies the missing gene, using a virus that’s been modified so it won’t cause illness but ferries the DNA instructions to liver cells, which use them to make the clotting factor. The treatment is given through an IV. In a study published

and more »

Continue reading

2017-12-08 NEWS

Seeking Alpha

CRISPR Therapeutics: Analysis Of And Update On The B-Thalassemia Franchise
Seeking Alpha
The company recently submitted a CTA for CTX-001 (the potential treatment for the blood disorder Beta-thalassemia). It’s the first application for the CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a potentially revolutionary platform to launch a